Study guide

8.4 Drug Administration & Therapy Management

Illinois MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Illinois MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Chapter 2: Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & Illinois Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Chapter 3: Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 Chapter 4: IDFPR, Licensure & Eligibility

4.1 IDFPR Authority & Sources of Illinois Pharmacy Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & Experiential Requirements

5 Chapter 5: Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 Impaired Practitioners & Mandatory Reporting

6 Chapter 6: Technicians, Interns & Supervision

6.1 Technician Registration, Training & Certification 6.2 Supervision, Scope & No Fixed Tech Ratio 6.3 Intern Scope, Delegation & Final Verification

7 Chapter 7: Prescription Authority & Validity

7.1 Who May Prescribe in Illinois 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (720 ILCS 570 + Federal) 7.4 Refills, Partial Fills & E-Prescribing Mandate

8 Chapter 8: Advanced IL Pharmacist Practice

8.1 Collaborative Practice Agreements & Clinical Services 8.2 Immunizations & Vaccine Administration 8.3 Naloxone Access & Opioid Antagonists 8.4 Drug Administration & Therapy Management

9 Chapter 9: Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs

10 Chapter 10: ILPMP & Opioid Public-Health Laws

10.1 Illinois PMP Overview, Reporting & Access 10.2 Mandatory Queries, Designees & Documentation 10.3 Legitimate Medical Purpose & Red Flags

11 Chapter 11: Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Chapter 12: Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Automated Systems & Self-Service Kiosks 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Delivery & Remote Services

13 Chapter 13: Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Illinois Compounding Rules & Beyond-Use Dates

14 Chapter 14: Test-Day Strategy & Final Review

14.1 When Illinois Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

8.4 Drug Administration & Therapy Management

Key Takeaways Explain This Topic AI

Practice of pharmacy drug administration under 225 ILCS 85/3(d)(4) includes patient-education administration plus specified injectable pathways (vaccines; hydroxyprogesterone caproate; long-acting injectables for mental health or substance use disorders) under prescription/training/notification rules.

Pharmacists may order and administer COVID-19 therapeutics subcutaneously, intramuscularly, or orally under 3(d)(16) with physician notification and record retention (or hospital P&T policies) for FDA-authorized products used as approved.

Under 3(d)(17), pharmacists may order and administer point-of-care tests, screenings, and treatments for influenza, SARS-CoV-2, Group A Streptococcus, RSV, adult-stage head louse, and conditions identified in a statewide public health emergency—using CLIA-waived tests or established statewide-protocol screening procedures.

Pharmacists may delegate administrative and technical tasks of performing listed tests to registered pharmacy technicians or student pharmacists under pharmacist supervision; clinical judgment and overall responsibility remain with the pharmacist.

Therapy management success on the exam hinges on supervision, documentation, notification/referral, and staying inside statute-listed conditions—not inventing unlimited disease lists or unsupervised tech clinical practice.

Last updated: August 2026

8.4 Drug Administration & Therapy Management

Quick Answer: NABP competency 2.2 asks when pharmacists and non-pharmacist personnel may participate in administration and therapy management . In Illinois, start with 225 ILCS 85/3(d) : administration is limited to defined pathways (patient education; vaccines; certain injectables), plus COVID-19 therapeutics ( 3(d)(16) ) and point-of-care testing/screening/treatment for a listed set of conditions ( 3(d)(17) ) using CLIA-waived tests or established statewide protocol screening. Techs/students may perform administrative/technical testing tasks under supervision and may administer certain vaccines under 9.6 . Always document, notify the patient’s physician when required, and refer when results or clinical status demand it.

This section stitches together administration, MTM/protocol care, and test-and-treat without re-teaching the entire immunization chapter.

Competency Area 2.2 Decision Frame

On every administration/therapy-management stem, run this checklist:

What act is being performed (inject, educate, test, treat, modify therapy)?

Who is the actor (pharmacist, student pharmacist, registered tech, clerical)?

What authority exists (patient-specific Rx, standing order, hospital P&T, statutory ordering authority)?

What training is required?

What supervision is required if non-pharmacists participate?

What documentation, notification, and referral are required?

Does the answer invent diseases or ages not in statute? If yes → wrong.

Drug Administration Pathways in 3(d)(4)

The practice of pharmacy includes drug administration limited to oral, topical, injectable, and inhalation as follows :

(A) Patient education on proper use or delivery

Pharmacists may administer in the context of teaching proper use/delivery (e.g., technique demonstration frameworks contemplated by the statute). This is education-linked administration , not a blank “inject anything.”

(B) Vaccinations (age 7+)

Covered in Section 8.2: Rx or standing order , training, adverse-reaction competence, physician notification, records (or hospital P&T).

(C) Alpha-hydroxyprogesterone caproate injections

Administration pursuant to a valid prescription by a physician licensed in all its branches, after appropriate training (contraindications/adverse reactions per rule), with notification to the patient’s physician and record retention , or hospital P&T policies.

(D) Long-acting injectables for mental health or substance use disorders

Administration pursuant to a valid prescription by the patient’s physician, APRN , or physician assistant , after ACPE-accredited appropriate training (including contraindications/adverse reactions per rule), with notification and record retention, or hospital P&T policies.

Exam contrast: Vaccine standing-order pathways are broad public-health tools; LAI mental health/SUD language emphasizes a valid prescription from the patient’s authorized prescriber plus ACPE training—not casual walk-up injection without that framework.

COVID-19 Therapeutics: 3(d)(16)

Pharmacists may order and administer COVID-19 therapeutics subcutaneously, intramuscularly, or orally with notification to the patient’s physician and appropriate record retention , or pursuant to hospital P&T policies. Eligible therapeutics are FDA approved, authorized, or licensed and must be administered in accordance with that approval/authorization/licensing.

Techs/students: 9.6(b) allows administration of COVID-19 therapeutics under a parallel supervision/training/CPR/immediate-availability structure—still not unsupervised clinical freelancing.

Test-and-Treat / CLIA-Waived Testing: 3(d)(17)

Illinois expressly includes ordering and administration of point-of-care tests, screenings, and treatments for:

  • Influenza
  • SARS-CoV-2
  • Group A Streptococcus
  • Respiratory syncytial virus (RSV)
  • Adult-stage head louse

Health conditions identified by a statewide public health emergency (as defined in the Illinois Emergency Management Agency Act)

…with notification to the patient’s physician, if any , and appropriate record retention , or hospital P&T policies.

Eligible tests and clinical decision tools

Eligible tests/screenings are those FDA approved, authorized, or licensed and used in accordance with that status

A pharmacist who orders/administers tests or screenings for these conditions may use a test that may guide clinical decision-making for the health condition that is waived under CLIA (Clinical Laboratory Improvement Amendments of 1988) and regulations, or any established screening procedure established under a statewide protocol

Do not invent a free-form disease list (e.g., “any infection,” “all chronic diseases,” “cancer screening panels”) beyond the statute. Emergency-declared conditions expand only when the statewide public health emergency mechanism applies.

Delegation of technical testing tasks

A pharmacist may delegate the administrative and technical tasks of performing a test for the listed conditions to a registered pharmacy technician or student pharmacist acting under the supervision of the pharmacist .

May delegate (when supervised) May not rebrand as tech-independent

Administrative/technical steps of performing the listed test Clinical decision to treat outside pharmacist responsibility

  • Tasks within training and pharmacy procedure Counseling/clinical conflict resolution reserved to pharmacists
  • Support collecting specimens as protocol allows Unsupervised “test-and-treat clinics” run only by techs
  • Reimbursement nondiscrimination note (awareness-level)

The Act states testing/screening/treatment ordered under this paragraph shall not be denied reimbursement under health benefit plans within the pharmacist’s license scope and shall be covered as if performed by a physician/APRN/PA, and bars certain PBM/carrier discrimination against pharmacists acting within scope. Jurisprudence exams rarely grade fee schedules; they do test that these services are within licensed pharmacist practice when statutory conditions are met.

Recordkeeping, Notification & Referral Duties

Across administration and test-and-treat, Illinois repeatedly requires:

Appropriate record retention of the service

Notification to the patient’s physician/primary provider when the statute says so (“if any” appears in the test-and-treat notification clause—still notify when a physician is identified)

Referral when clinically indicated (e.g., reactive HIV testing under PrEP/PEP pathways in 43.5 ; pediatric well-child referrals in vaccine rules; emergency care after severe reactions)

  • Compliance with VAERS /adverse-event reporting for vaccines
  • I-CARE or PCP within 30 days for vaccine administration under Part 1330.50
  • Hospital settings: follow P&T documentation systems when that pathway is used
  • Therapy management documentation (connect to 8.1)

When the service is MTM under a standing order, remember retail MTM’s ≤48-hour communication to prescribers for documented services. Test-and-treat notification language is related in spirit: the physician relationship is not discarded because the pharmacist initiated a protocol service.

Personnel Participation Matrix (Administration & Testing)

Act Pharmacist Student pharmacist Registered tech

Clinical decision to order protocol vaccine/test/treat within statute Yes, when authorized Learning participation under direct supervision—not independent No independent clinical ordering authority

Inject vaccines age 7+ under Rx/standing order Yes if trained Under direct pharmacist supervision per rules Limited; COVID-19/RSV/influenza under 9.6 conditions

Technical steps of listed POC tests Yes Yes under supervision Yes administrative/technical under supervision

Full counseling / DUR / clinical conflict resolution Yes Supervised learning No (except limited counseling support)

LAI mental health/SUD injection Trained pharmacist under valid Rx framework Only under pharmacist supervision models—not a tech substitute Not the 9.6 vaccine list; do not assume tech administration

Integrated Exam Scenarios

Scenario A — Strep test-and-treat. Adult with pharyngitis symptoms; pharmacist uses CLIA-waived Group A strep test and treats under 3(d)(17) with documentation and physician notification. Within statutory list.

Scenario B — Invented disease. Pharmacist claims authority to independently test-and-treat hypertension, diabetes, and depression under the same paragraph without additional protocols. Not supported by the listed 3(d)(17) conditions (those chronic diseases are not on the statutory POC list).

Scenario C — Tech runs the clinic. Tech performs CLIA-waived flu test and independently decides treatment and counseling while pharmacist is off-site. Technical task delegation requires pharmacist supervision ; independent clinical management fails.

Scenario D — LAI antipsychotic. Patient presents with valid prescription from treating psychiatrist/APRN/PA; pharmacist completed ACPE training for LAI administration and notifies the prescriber/retains records. Fits 3(d)(4)(D) framework.

Scenario E — Education administration. Pharmacist demonstrates/administers in teaching proper inhaler or injection technique as contemplated by 3(d)(4)(A) . Distinguish from unauthorized administration of unrelated injectables without Rx/protocol.

  • Common Traps
  • Expanding test-and-treat beyond the listed conditions (plus true statewide emergency conditions)
  • Forgetting CLIA-waived or statewide protocol as the testing tools
  • Allowing techs to own clinical treatment decisions
  • Skipping physician notification/record retention
  • Confusing vaccine standing-order rules with LAI mental health/SUD prescription requirements
  • Assuming federal CLIA certificate details replace Illinois scope limits
  • Chapter 8 Synthesis
  • Theme Illinois anchor
  • Collaborative / protocol care MTM + standing orders ( 3(aa), 3(dd) ); service-specific statutes

Vaccines Age 7+ ; Rx/standing order; training; 1330.50 VIS/5-yr/I-CARE-or-PCP-30-day; tech COVID/RSV/flu under 9.6

Opioid antagonists 19.1 standardized procedures; standing order access; offer with opioid dispensing; educate

Administration & test-and-treat 3(d)(4), (16), (17) ; CLIA-waived/statewide protocol; supervised technical delegation; notify & document

Master the matrix of who / what / under what order / with what records . That is how Illinois advanced-practice items convert from anxiety into statute-driven answers. Next chapters return to counseling, DUR, and patient safety —the everyday duties that still apply when clinical services expand.